Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
Rhea-AI Summary
Aclarion (Nasdaq: ACON, ACONW) announced that its Board adopted a limited duration stockholder rights plan effective March 19, 2026 that expires in one year. The Rights Plan is intended to help stockholders realize long-term value and to reduce the likelihood of control changes without an appropriate premium.
The plan applies equally to all current and future stockholders, was adopted unanimously by the Board, and was not adopted in response to any specific acquisition proposal.
Positive
- One-year rights plan effective immediately, providing a defined review period
- Applies equally to all current and future stockholders
- Board unanimous adoption signals coordinated governance action
Negative
- Limits unsolicited control efforts for one year, potentially delaying offers
- May restrict rapid activist or takeover strategies during the plan term
News Market Reaction – ACON
On the day this news was published, ACON declined 1.81%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ACON showed its own move while only one momentum peer, BFRG, appeared, moving up ~5.1%, indicating stock-specific trading around this rights plan news rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Conference participation | Positive | +0.6% | ROTH Conference meetings highlighting Nociscan progress and strong, debt-free balance sheet. |
| Mar 12 | Conference attendance | Positive | -3.2% | CEO attending LSI USA 2026 to meet investors and partners about NOCISCAN. |
| Feb 05 | Shareholder letter | Positive | -12.6% | Shareholder letter detailing CLARITY trial plans, cash runway into 2028 and capital status. |
| Feb 03 | Commercial expansion | Positive | -2.1% | Agreement with Source Healthcare to integrate Nociscan and build real-world evidence. |
| Jan 13 | Financing / runway | Positive | -6.9% | $10.4M common-stock financing, $21.6M cash, debt-free balance sheet and runway into 2028. |
Recent positive corporate updates often saw negative price reactions, suggesting a pattern of selling into good news.
Over recent months, Aclarion issued several positive updates, including conference participation and balance sheet improvements. A $10.4 million financing left the company debt-free with $21.6 million in cash and runway into 2028. The company expanded Nociscan via a Source Healthcare agreement and highlighted catalysts and a strong balance sheet at investor conferences. Despite these developments, four of the last five news events saw negative 24-hour price reactions, indicating a tendency for the stock to trade lower following constructive announcements.
Market Pulse Summary
This announcement details a limited duration stockholder rights plan, effective immediately and expiring in one year, designed to ensure all investors benefit from any future change-of-control premium and to give the Board time to evaluate proposals. In the past six months, Aclarion has strengthened its balance sheet and extended runway into 2028 while advancing Nociscan adoption and the CLARITY trial. Investors may monitor how this governance step interacts with prior equity financings and future strategic options.
Key Terms
stockholder rights plan financial
AI-generated analysis. Not financial advice.
BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”). The Rights Plan is effective immediately and expires in one year.
The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to make informed decisions that are in the best interest of Aclarion and its stockholders.
The Rights Plan applies equally to all current and future stockholders. The Rights Plan was not adopted in response to any specific proposal to acquire control of the Company and is not intended to deter offers or preclude the Board from considering offers that are fair and otherwise in the best interests of all the Company’s stockholders.
About the Rights Plan
The terms of the Rights Plan are similar to those of plans adopted by other publicly traded companies. Pursuant to the Rights Plan, Aclarion declared a dividend distribution of one preferred stock purchase right for (i) each share of the Company’s common stock, par value
One right will automatically attach to each share of Common Stock and each Rights-Eligible Warrant, including shares of Common Stock and additional Rights-Eligible Warrants, if any, that become issued and outstanding after the Record Date and before the rights become exercisable. Initially, these rights will not be exercisable and will trade with, and be represented by, the Common Stock and the Rights-Eligible Warrants, as applicable.
Each right entitles the registered holder thereof to purchase from the Company one one-thousandth (1/1,000th) of a share of Series D Junior Participating Preferred Stock, par value
Under the Rights Plan, the rights will become exercisable if an entity, person or group (the “acquiring person”) acquires beneficial ownership of
In the event that the rights become exercisable due to the triggering ownership threshold being crossed, each right will entitle its holder (other than the person, entity or group triggering the Rights Plan, whose rights will become void and will not be exercisable) to receive shares of Common Stock having a market value equal to two times the exercise price of the right. In addition, in the event of a merger or similar change of control of the Company, each right will entitle its holder (other than the person, entity or group triggering the Rights Plan, whose rights will become void and will not be exercisable) to receive shares of common stock of the acquiring company having a market value equal to two times the exercise price of the right. The Board, at its option, may exchange each right (other than rights owned by the acquiring person that have become void) in whole or in part, at an exchange ratio of one share of Common Stock per outstanding right, subject to adjustment. Except as provided in the Rights Plan, the Board is entitled to redeem the rights, at
Under the Rights Plan, any person, entity or group that currently owns more than the triggering percentage prior to the Company’s announcement of its adoption of the Rights Plan may continue to own its shares of Common Stock without being deemed an acquiring person but may not acquire any additional shares of Common Stock, or form a group with another owner of Common Stock, without triggering the Rights Plan. The Rights Plan does not contain any dead-hand, slow-hand, no-hand or similar feature that would limit the ability of a future Board to redeem the rights.
The Rights Plan will expire on March 18, 2027, unless earlier redeemed or exchanged by the Board or terminated upon the closing of any merger or other acquisition transaction involving the Company pursuant to an agreement approved by the Board prior to any person becoming an acquiring person.
Additional information regarding the Rights Plan and a copy of the plan will be contained in a current report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.
Goodwin Procter LLP is serving as legal counsel for Aclarion.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. For more information, please visit www.aclarion.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements include, without limitation, implied and express statements relating to the anticipated benefits and expected consequences of the rights plan that Aclarion has adopted. Words such as “anticipate,” “believe,” “continue,” “could,” “designed,” “endeavor,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “preliminary,” “will,” “would” and similar expressions are intended to identify forward-looking statements. Any express or implied forward-looking statements included in this press release are based on current expectations, are only predictions and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those indicated, including, without limitation, the effectiveness of the rights plan in providing the Board of Directors with time to make informed decisions that are in the best long-term interests of Aclarion and its stockholders. These and other factors that could affect actual results are discussed more fully in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2025 and other filings made with the U.S. Securities and Exchange Commission from time to time. Any forward-looking statements contained in this press release represent Aclarion’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Aclarion explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contact:
Jessica Starman
media@aclarion.com
FAQ
What did Aclarion (ACON) announce on March 19, 2026 about a rights plan?
How long is the Aclarion (ACON) stockholder rights plan effective for?
Does the Aclarion (ACON) rights plan target any specific bidder or proposal?
Who does the Aclarion (ACON) rights plan cover among shareholders?
What is the stated purpose of Aclarion's (ACON) one-year rights plan?
